GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Searches for “Ozempic face” surge as people look for filler-based solutions

Public interest in “Ozempic face” rose sharply from 2022 to 2025, mirrored by increased searches for nonsurgical facial filler procedures. Surgical terms showed neutral or negative associations, indicating consumers are primarily exploring filler-based solutions for GLP-1RA-related facial volume loss.

20 Nov 2025

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects.

20 Nov 2025

Oral semaglutide delivers real-world drops in blood sugar and weight in diabetes trial

Oral semaglutide delivered meaningful reductions in HbA1c and body weight among GLP-1RA-naïve adults with type 2 diabetes in a Dutch real-world cohort. Lipid levels and blood pressure showed only small changes, reflecting modest cardiometabolic effects outside glucose and weight control.

18 Nov 2025

Tirzepatide reveals a brain signal that predicts returning food preoccupation

Researchers implanted electrodes in the human nucleus accumbens to track brain activity during severe food preoccupation in an individual taking tirzepatide. They found that a delta–theta biomarker disappeared during symptom-free periods and re-emerged weeks before relapse, suggesting a possible neural marker of vulnerability to dysregulated eating.

18 Nov 2025

Brain recordings reveal short-lived effects of tirzepatide on food cravings

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" thought to be involved in food noise – but only temporarily.

17 Nov 2025

High protein breakfasts help you feel fuller but do not change how much you eat later

High protein breakfasts, whether plant or animal-based, boosted GLP-1 and PYY and modestly reduced appetite compared with a low protein, high carbohydrate meal. Despite these hormonal and appetite changes, lunchtime energy intake remained unchanged in both younger and older adults.

13 Nov 2025

Off-label GLP-1 use highlights the cultural pressures driving body anxieties

New obesity drugs that were designed to treat diabetes and obesity are increasingly being used off-label by people without these conditions to achieve slimness and social approval rather than health gains. This perspective maps how such pharmacological thinness interacts with stigma, beauty ideals, digital culture, and inequality, and calls for multinational, intersectional research to understand its full impact.

13 Nov 2025

What The Health? From KFF Health News: The government is open

The longest federal government shutdown in history is over, after a handful of House and Senate Democrats joined most Republicans in approving legislation that funds the government through January. Despite Democrats' demands, the package did not include an extension of the expanded tax credits that help most Affordable Care Act enrollees afford their plans — meaning most people with ACA plans are slated to pay much more toward their premiums next year.

13 Nov 2025

Mursla Bio collaborates with a leading global pharma company to advance biomarker-guided precision medicine in MASH

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.

From Mursla Bio 13 Nov 2025

GLP-1 drugs linked to improved survival in colon cancer patients

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists - the class of drugs behind Ozempic, Wegovy and Mounjaro, for example - may do more than regulate blood sugar and weight.

11 Nov 2025

Metformin shows promise in treating AFib recurrence after ablation

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Novel triple receptor agonist shows potent efficacy in lowering high triglycerides

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients with severe hypertriglyceridemia by more than 60%, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar blood sugar control but significantly greater reductions in body mass index than metformin. These findings highlight the potential of high-potency GLP-1 agents as effective monotherapy options in managing obesity and glycemic control in adolescents.

10 Nov 2025

Diabetes drugs semaglutide and tirzepatide show real-world heart benefits

In a large real-world analysis across three U.S. healthcare databases, semaglutide and tirzepatide showed cardiovascular benefits consistent with randomized trials. Semaglutide lowered heart attack and stroke risk versus sitagliptin, while tirzepatide performed comparably to dulaglutide and semaglutide over one year.

10 Nov 2025

Weight loss drugs used by patients with high triglycerides do not increase pancreatitis risk

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events.

10 Nov 2025

Genetic and cellular mechanisms underlying steatotic liver disease

Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic dysfunction and ALD (MetALD), has emerged as the dominant cause of chronic liver disease worldwide, displacing viral hepatitis as the primary aetiology.

10 Nov 2025

Do GLP-1 drugs cause cancer? New review says no, may even protect

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and increased cancer risk, countering early safety concerns. Instead, evidence suggests possible protective effects for certain cancers, supported by metabolic and immune-modulating mechanisms.

4 Nov 2025

GLP-1 drugs calm inflammation beyond diabetes and weight loss

This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent mechanisms. It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.

4 Nov 2025

Resistance exercise may offer greater benefits for preventing diabetes and obesity

Running may help burn calories, but when it comes to preventing diabetes and obesity, pumping iron might have the edge, according to preclinical findings from the Fralin Biomedical Research Institute at VTC.

4 Nov 2025

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Searches for “Ozempic face” surge as people look for filler-based solutions

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Oral semaglutide delivers real-world drops in blood sugar and weight in diabetes trial

Tirzepatide reveals a brain signal that predicts returning food preoccupation

Brain recordings reveal short-lived effects of tirzepatide on food cravings

High protein breakfasts help you feel fuller but do not change how much you eat later

Off-label GLP-1 use highlights the cultural pressures driving body anxieties

What The Health? From KFF Health News: The government is open

Mursla Bio collaborates with a leading global pharma company to advance biomarker-guided precision medicine in MASH

GLP-1 drugs linked to improved survival in colon cancer patients

Metformin shows promise in treating AFib recurrence after ablation

Novel triple receptor agonist shows potent efficacy in lowering high triglycerides

GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes

Diabetes drugs semaglutide and tirzepatide show real-world heart benefits

Weight loss drugs used by patients with high triglycerides do not increase pancreatitis risk

Genetic and cellular mechanisms underlying steatotic liver disease

Do GLP-1 drugs cause cancer? New review says no, may even protect

GLP-1 drugs calm inflammation beyond diabetes and weight loss

Resistance exercise may offer greater benefits for preventing diabetes and obesity

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in